Hapag-Lloyd Bookings Double on China-US Route in Weeks After Tariff Truce
Bookings out of China more than doubled in the three weeks after the 90-day trade truce was put into effect, according to CEO Rolf Habben Jansen.
More from Sourcing Journal
Guess Limits Tariff Impact to Less Than $10M, Adjusts Sourcing and Buying Strategies
Panama Canal Sees Post-Drought Spike in Container Shipping Transits
US Trade Deficit Contracted in April Amid Tariff-Driven Import Paralysis
'We now need to see over the upcoming couple of weeks what is going to happen, and how much of that cargo rush is going to remain,' said Habben Jansen in a recent online panel discussion hosted by the ocean carrier.
Despite various projections calling for a contraction in global container volumes for the year, Hapag-Lloyd revised its outlook upward from its previous flat growth forecast on the back of the recent uptick, projecting global container demand to increase 4 percent.
'I would still expect us to see decent growth in the second quarter,' said Habben Jansen.
While China-to-U.S. volumes account for roughly 5 percent of Hapag-Lloyd's total business, the U.S. overall represents 27 percent of its volumes, Habben Jansen said. Approximately 22 percent of global container flows at the company go through American ports.
With the U.S. remaining a sizable chunk of the liner's business, the concerns of volatility stemming from the stop-and-start nature of President Donald Trump's tariff decisions makes it challenging to plan for.
Case in point, in the company's earnings call in mid-May, the CEO said Hapag-Lloyd saw bookings decrease 20 percent on average in the period after the Liberation Day tariffs were applied and ahead of the tariff rollback.
But the China-to-U.S. demand picked up so quickly that Hapag-Lloyd and Gemini Cooperation partner Maersk introduced a new direct trans-Pacific service with a rotation of Xiamen, China; Busan, South Korea; and Long Beach, Calif.. The first sailing will take place out of Xiamen on June 24.
The 'WC6' service will connect Busan and Long Beach with a transit time of 14 days, and a competitive direct Xiamen service into Long Beach in 18 days.
Hapag-Lloyd's move reflects the industry at large, which has sought to add more capacity on the trans-Pacific trade lane to capitalize on shippers' rush to get cargo space ahead of tariff deadlines in July and August.
As the Gemini alliance partners prep to start their new service offering, the carriers still lead the pack when it comes to schedule reliability, keeping their 90 percent schedule reliability goal intact across March and April. The alliance expects to be fully 'phased in' by July, meaning that all shared vessels will sail on Gemini schedules.
'Only then will it be possible to truly evaluate their performance,' said Alan Murphy, CEO of Sea-Intelligence, in the monthly update.
Gemini Cooperation officially came in with 90.7 percent reliability, with MSC following suit far behind at 69.8 percent. The Premier Alliance of Ocean Network Express (ONE), HMM and Yang Ming recorded 53 percent reliability in the two-month stretch.
Habben Jansen said he was encouraged by the alliance's ability to ensure Hapag-Lloyd's first-quarter volumes surpassed the wider market with 9 percent growth, ahead of the 4.2 percent global growth experienced by the wider container shipping sector.
'That was the intention when we started [the partnership]. We knew that we needed to attract more volumes to fill those ships, also because we lose fewer sailings as we don't do blank sailings, as we used to do,' Habben Jansen said. 'And we sail on time, which basically means that we can use the ships more often. It's very nice to see that also reflected in the numbers, and hopefully we'll see more of that as we move into Q2.'
Although competitor CMA CGM has introduced another service line back on the Suez Canal route, Hapag-Lloyd does not have intentions of following suit—the attitude still taken by most major container shipping firms.
According to Habben Jansen, the story remains the same. There must be a clear indication that vessels and crew will be safe from potential Houthi attacks.
'If we go back then we will have to do that step by step, as we would like to avoid chaos in the Mediterranean and in Europe in particular, and to a lesser extent, on the East Coast of the U.S.,' said Habben Jansen. 'Right now, we do not see any signs that it is going to be and remain safe in the near future.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
12 minutes ago
- Los Angeles Times
D.Law Named to Inc.'s 2025 Best Workplaces List
The annual list recognizes the businesses that set the standard for workplace success and awards excellence in company culture is proud to announce it has been named to Inc.'s 2025 Best Workplaces list, honoring companies that have built exceptional workplaces and vibrant cultures that support their teams and businesses. This year's list, featured on is the result of comprehensive measurement and evaluation of American companies that have excelled in creating exceptional workplaces and company cultures – whether inperson or remote. The award process involved a detailed employee survey conducted by Quantum Workplace, covering critical elements such as management effectiveness, perks, professional development and overall company culture. Each company's benefits were also audited to determine overall score and ranking. is honored to be included among the 514 companies recognized this year. 'At we believe our people are the heartbeat of everything we do. From professional growth opportunities to team celebrations and community involvement, we're committed to cultivating a workplace where everyone feels empowered, supported, and inspired to do their best work,' said Emil Davtyan, founder and managing attorney. 'Being named one of Inc.'s Best Workplaces confirms that our focus on people-first culture makes a meaningful difference. We're proud to be part of a new generation of firms that are redefining what it means to be in this profession.' Founded in 2015, is a purpose-driven law firm focused on providing compassionate, effective legal services to clients across California. With a team-oriented approach and an emphasis on continuous learning, has quickly built a reputation for both its client service and its inclusive internal culture. The firm is part of a growing movement to redefine what it means to be an employment law firm by putting people, empathy and impact at the center of everything it does. 'Inc.'s Best Workplaces program celebrates the exceptional organizations whose workplace cultures address their employees' welfare and needs in meaningful ways,' says Bonny Ghosh, editorial director at Inc. 'As companies expand and adapt to changing economic forces, maintaining such a culture is no small feat. Yet these honorees have not only achieved it – they continue to elevate the employee experience through thoughtful benefits, engagement, and a deep commitment to their teams. is an employment law firm dedicated to defending the rights of workers under California employment law. Based in Los Angeles with offices throughout the state, represents workers in every industry, whether they work for large corporations or small companies. specializes in the full range of employment law, including wrongful termination, pay and overtime issues, discrimination and harassment, workplace retaliation, leaves of absence and more. attorneys have over 350 years of collective experience in employment law and have helped over 150,000 workers get more than $1.5 billion in settlements.
Yahoo
3 hours ago
- Yahoo
Bernstein Reiterates Outperform on TSMC (TSM), Citing Strategic Chip Role
Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM) is one of the best growth stocks to buy according to analysts. On August 15, Bernstein reiterated its Outperform rating on Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), with a price target of $249.00. That represents an implied upside of only 4.1% from the current price of $239.1. A close-up of a complex network of integrated circuits used in logic semiconductors. However, Bernstein cited the Taiwanese company's strategic importance in the global semiconductor landscape, emphasizing that it accounts for roughly 15–25% of the worldwide wafer fab equipment (WFE) market. That is massive, especially considering the whole of China's share of 30–40%. Bernstein also cited that a significant share of the company's capital expenditures is allocated beyond just traditional wafer fabrication. According to the firm, TSMC is increasingly investing higher amounts in infrastructure, packaging, and testing technologies. These are critical components in advanced chip production. Last month, the company delivered a stellar Q2 2025 performance, with revenue climbed to NT$933.79 billion (US $30.07 billion), up 38.6 % year-over-year; while net income reached NT$398.27 billion (about US $13.53 billion), and diluted EPS came in at NT$15.36 (US $2.47 per ADR), a whopping 60.7 % jump year-over-year. While we acknowledge the potential of TSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
3 hours ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
